북미의 수의 종양학 시장 규모, 점유율, 동향 분석 보고서 : 동물별, 치료별, 암별, 국가별, 부문별 예측(2025-2030년)

North America Veterinary Oncology Market Growth & Trends:

The North America veterinary oncology market size is expected to reach USD 1.22 billion by 2030, expanding at a CAGR of 10.70% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising incidence of cancer in pets, the number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies, and the increasing penetration of pet insurance. Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth. For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform.

During COVID-19, the market witnessed dampened growth owing to several challenges. The pandemic impacted veterinary cancer research & development efforts and the logistics supply of crucial pet pharmaceuticals. It also limited access to veterinary care. According to the Global Animal Health Association's 2020 report, pet owners in a study said that in many countries, veterinarian services were hampered by delayed or skipped care for pets. The pandemic, however, also accelerated the adoption of digital technologies to enhance care. In March 2020, PetCure Oncology upgraded its Telehealth options to enable pet families and referring veterinarians to remotely connect with its board-certified radiation oncologists.

The market is fragmented and competitive due to the presence of several small-to-large market players. Players are actively involved in deploying strategic initiatives to gain market share. For instance, in January 2022, Dechra acquired the rights to sell, market, and support Laverdia-CA1 (verdinexor tablets) in the U.S. from Anivive Lifesciences, Inc. In June 2022, Boehringer Ingelheim International GmbH entered into a research partnership with CarthroniX, a biopharma company, to develop small molecule therapeutics in canine oncology. In April 2023, Torigen Pharmaceuticals partnered with Veterinary Management Groups (VMG) to provide their experimental autologous prescription products and services to the latter's more than 2,000 member clinics network.

North America Veterinary Oncology Market Report Highlights:

• Based on animal type, the canine segment dominated the market in 2024 with a revenue share of over 86.25%. The feline segment, on the other hand, is projected to grow at the fastest CAGR of over 12.38% over the forecast period. This is attributed to the increasing partnerships and collaborations to further the development and launch of reliable veterinary cancer therapies. In October 2022, Ardent Animal Health, for example, completed a license agreement for a novel checkpoint inhibitor for canine cancer treatment
• In terms of therapy, the surgery segment dominated the market in 2024 with a revenue share of over 36.09%. Immunotherapy segment is estimated to grow at the fastest CAGR over the forecast period.
• Based on cancer type, the skin cancers segment dominated the market in 2024 with a revenue share of over 39.01%. The others segment is expected to grow at the fastest CAGR over the forecast period.
• Based on country, The veterinary oncology market in the U.S. held the largest share of 89.02% in the North American region in 2024 The growth in the U.S. is attributed to the presence of key players and strategic initiatives by market players. In April 2023, Torigen Pharmaceuticals opened a new production facility and headquarters in Farmington, Connecticut, U.S.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Scope
  • 1.1.2. Estimates And Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
  • 1.6.2. Global Market: CAGR Calculation
• 1.7. Research Scope and Assumptions
  • 1.7.1. List of Secondary Sources
  • 1.7.2. List of Primary Sources
  • 1.7.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. North America Veterinary Oncology Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing Prevalence Of Cancer In Pets
    • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
    • 3.2.1.3. Growing Focus On Animal Safety
    • 3.2.1.4. Growing Uptake Of Pet Insurance
    • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
    • 3.2.1.6. Increase In Pet Population
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Adverse effects associated with therapies
    • 3.2.2.3. Complex Regulatory Guidelines
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. North America Veterinary Oncology Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal landscape
• 3.4. Covid-19 Analysis
• 3.5. Estimated Pet Population, by key countries

Chapter 4. North America Veterinary Oncology Market: Animal Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. North America Veterinary Oncology Market Movement Analysis
• 4.3. North America Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
• 4.4. Canine
  • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.5. Feline
  • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.6. Equine
  • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Veterinary Oncology Market: Therapy Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. North America Veterinary Oncology Market Movement Analysis
• 5.3. North America Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
• 5.4. Radiotherapy
  • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Stereotactic Radiation Therapy
    • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.2. LINAC
      • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2.3. Other Type
      • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Conventional Radiation Therapy
    • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Surgery
  • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Chemotherapy
  • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Immunotherapy
  • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. Other Therapies
  • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. North America Veterinary Oncology Market Movement Analysis
• 6.3. North America Veterinary Oncology Market Size & Trend Analysis, by Cancer type, 2018 to 2030 (USD Million)
• 6.4. Skin Cancer
  • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Lymphomas
  • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Sarcomas
  • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. North America Veterinary Oncology Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Insights
    • 7.3.2.3. U.S. Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Insights
    • 7.3.3.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Insights
    • 7.3.4.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Position Analysis/ Heat Map Analysis
• 8.3. Estimated Company Market Share Analysis, 2023
• 8.4. Strategy Mapping
  • 8.4.1. Mergers & Acquisitions
  • 8.4.2. Partnerships & Collaborations
  • 8.4.3. Others
• 8.5. Company Profiles
  • 8.5.1. Elanco
    • 8.5.1.1. Participant's Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Boehringer Ingelheim International GmbH.
    • 8.5.2.1. Participant's Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Zoetis
    • 8.5.3.1. Participant's Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. PetCure Oncology
    • 8.5.4.1. Participant's Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Accuray Incorporated
    • 8.5.5.1. Participant's Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Varian Medical Systems, Inc.
    • 8.5.6.1. Participant's Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Elekta AB.
    • 8.5.7.1. Participant's Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Karyopharm Therapeutics, Inc.
    • 8.5.8.1. Participant's Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Virbac.
    • 8.5.9.1. Participant's Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Merck & Co., Inc.
    • 8.5.10.1. Participant's Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives
  • 8.5.11. Dechra Pharmaceuticals PLC
    • 8.5.11.1. Participant's Overview
    • 8.5.11.2. Financial Performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic Initiatives
  • 8.5.12. NovaVive Inc.
    • 8.5.12.1. Participant's Overview
    • 8.5.12.2. Financial Performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic Initiatives
  • 8.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
    • 8.5.13.1. Participant's Overview
    • 8.5.13.2. Financial Performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic Initiatives

Chapter 9. Key Takeaways